Society of Nuclear Medicine and Molecular Imaging (SNMMI)

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), formerly the Society of Nuclear Medicine, is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging (PET and SPECT). The bulk of nuclear imaging exams relate to oncology, about a third to cardiac imaging and the rest for a variety of protocols, including imaging inflammation and beta-amyloid plaques that cause Alzheimer's disease. 

RSS icon
SNMMI Image of the Year 68Ga-FAPI-46 PET/CT heart attack acute myocardial infarction

‘Image of the Year’ highlights the predictive power of a new PET imaging agent

The Society of Nuclear Medicine and Molecular Imaging has chosen its 2022 Image of the Year, and it’s one that is sure to interest anyone in the field of cardiac imaging.

Thumbnail

Cutting radiation exposure in half during PET/CT using virtual CT scans

“High-quality artificial intelligence-generated images preserve vital information from raw PET images without the additional radiation exposure from CT scans,” experts involved in the study explained.

Thumbnail

First ever full course of the latest MR-guided radiation therapy treatments completed at Henry Ford Health

The Detroit-based cancer institute achieved this landmark moment using the MRIdian A3i, which is the latest enhancement of the MRIdian system from ViewRay, Inc.

Thumbnail

CMS coverage decision for Alzheimer's drug, related PET scans sparks concern in imaging community

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

brain money alzheimer dementia

Imaging industry advocate slams feds’ failure to address PET coverage gap in recent ruling

The Society for Nuclear Medicine & Molecular Imaging expressed "strong opposition" following CMS' decision, arguing there is no evidence to support limiting pay for such scans. 

FDA approves new radioligand therapy for PSMA positive metastatic prostate cancer

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression. 

Thumbnail

FDA approves new therapy, complementary imaging agent for treating metastatic prostate cancer

Provider advocates praised the decision, calling it “one of the greatest success stories in nuclear medicine history.”

Thumbnail

SNMMI selects first Radiopharmaceutical Therapy Centers of Excellence

The Society of Nuclear Medicine and Molecular Imaging's program was established to ensure that institutions adhere to the strict regulatory training, qualification and performance standards necessary to safely deliver radiopharmaceutical therapies.

Displaying 9 - 16 of 43
Design by Adaptive Theme